Biogen Inc (XSWX:BIIB) Stock News, Headlines & Updates
Biogen Inc Stock News from GuruFocus
- 1
- 2
- 3
Jul 22, 2025
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International Conference | BIIB stock news
GuruFocus News • 11:01pm
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
GlobeNewswire • 11:00pm
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International Conference | BIIB stock news
GuruFocus News • 8:03pm
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Marketwired • 7:00pm
Jul 21, 2025
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 | BIIB Stock News
GuruFocus News • 6:45pm
Biogen (BIIB) Commits Additional $2 Billion to North Carolina Expansion | BIIB Stock News
GuruFocus News • 7:16am
Biogen Inc (BIIB) Announces $2 Billion Investment in North Carolina Manufacturing Expansion | BIIB stock news
GuruFocus News • 7:11am
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
Marketwired • 7:00am
Biogen (BIIB) Increases Investment in North Carolina Manufacturing Facilities
GuruFocus News • 6:56am
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary | BIIB Stock News
GuruFocus News • 6:48am
Biogen (BIIB) Downgraded by Truist Amid Growth Concerns | BIIB Stock News
GuruFocus News • 5:46am
Jul 10, 2025
Biogen (BIIB) Presents Promising Data from Zorevunersen Studies | BIIB Stock News
GuruFocus News • 6:48am
Biogen (BIIB) Advances Phase 3 Study for Dravet Syndrome Treatment | BIIB Stock News
GuruFocus News • 6:32am
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Cong
GuruFocus News • 6:22am
Jul 08, 2025
Biogen Inc (BIIB) Stock Price Up 3.47% on Jul 8
GuruFocus News • 12:07pm
Jul 07, 2025
Biogen (BIIB) to Report Q2 Earnings with $46M Charge Impact
GuruFocus News • 3:56pm
Jul 01, 2025
Biogen Inc (BIIB) Trading 4.67% Higher on Jul 1
GuruFocus News • 12:07pm
Jun 30, 2025
Biogen (BIIB) Initiates Phase 3 Trial for Kidney Disease Treatment
GuruFocus News • 10:55am
Biogen Inc (BIIB) Launches Phase 3 Study for Felzartamab in Treating Rare Kidney Disease | BIIB stock news
GuruFocus News • 7:08am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Marketwired • 7:00am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy | BIIB Stock News
GuruFocus News • 6:45am
Jun 27, 2025
Biogen (BIIB) Unveils Promising Spinraza Data
GuruFocus News • 1:55pm
Biogen Inc (BIIB) Announces Promising Data on Nusinersen for SMA Treatment | BIIB stock news
GuruFocus News • 11:03am
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Marketwired • 10:00am
Biogen (BIIB) Highlights Promising Data on Nusinersen for SMA Treatment | BIIB Stock News
GuruFocus News • 9:16am
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | BIIB Stock News
GuruFocus News • 9:15am
Biogen (BIIB) Maintains Outperform Rating with Price Target of $213 | BIIB Stock News
GuruFocus News • 8:02am
Jun 26, 2025
BIIB: Analyst Reiterates Buy Rating and Maintains Price Target | BIIB Stock News
GuruFocus News • 7:30am
Jun 25, 2025
Biogen (BIIB) Advances SMA Treatment to Key Study Phase | BIIB Stock News
GuruFocus News • 1:30pm
Biogen (BIIB) Receives Price Target Upgrade from RBC Capital | BIIB Stock News
GuruFocus News • 9:34am
Biogen (BIIB) Receives Increased Price Target from RBC Capital | BIIB Stock News
GuruFocus News • 8:02am
Biogen Inc (BIIB) Announces Promising Phase 1 Results for Salanersen in Treating Spinal Muscular Atrophy | BIIB stock news
GuruFocus News • 7:06am
Biogen (BIIB) Reports Positive Phase 1 Results for Salanersen in SMA Treatment | BIIB Stock News
GuruFocus News • 7:01am
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Marketwired • 7:00am
Biogen (BIIB) Reports Promising Phase 1 Results for Salanersen in SMA Treatment | BIIB Stock News
GuruFocus News • 6:47am
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | BIIB Stock News
GuruFocus News • 6:45am
Jun 24, 2025
Biogen Inc. (BIIB) Announces Results of 2025 Annual Meeting of Stockholders
GuruFocus News • 7:00pm
Jun 18, 2025
Biogen Inc (BIIB) Initiates Phase 3 BRAVE Study for Pediatric Friedreich Ataxia Treatment | BIIB stock news
GuruFocus News • 8:16am
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Marketwired • 7:00am
Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxolone | BIIB Stock News
GuruFocus News • 6:48am
- 1
- 2
- 3
Show
Entries
Headlines
Total 0- 1
No recent news